What Is Bioequivalence? Pharmacy Concepts for Personal Injury Cases

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 4, 2026 | 6 min read

Bioequivalence is the FDA standard that determines whether a generic drug produces the same blood levels as the brand-name version. Understanding bioequivalence helps attorneys and patients interpret pharmacy lien records accurately.

Bioequivalence is a pharmacokinetic measurement confirming that a generic drug product produces the same rate and extent of absorption of the active ingredient as the reference (brand-name) product when administered at the same dose under the same conditions. Two products are bioequivalent when the 90% confidence interval for the ratio of their key pharmacokinetic parameters (AUC and Cmax) falls within the FDA-accepted range of 80% to 125%.

• Bioequivalence is the scientific standard that allows the FDA to approve generic drugs without requiring them to repeat full clinical trials
• A bioequivalent generic is expected to produce the same clinical effect as the brand-name drug in any given patient
• In personal injury cases, understanding bioequivalence helps attorneys interpret medication records where generic products are dispensed in place of brand-name prescriptions
• LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages
• As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "Bioequivalence is the foundation of generic drug approval — when a pharmacy lien record shows a generic product, attorneys can be confident it provides the same therapeutic effect as the brand"

How Bioequivalence Is Tested

The FDA requires generic drug manufacturers to conduct bioequivalence studies before granting approval. The standard study design is:

Crossover study — a group of healthy volunteers (typically 24 to 36 subjects) takes both the brand-name product and the generic product on separate occasions, with a washout period between doses. Blood samples are drawn at multiple time points after each dose to measure drug levels.

Key parameters measured:

• AUC (Area Under the Curve) — the total drug exposure over time. AUC reflects the extent of absorption — how much drug gets into the bloodstream.
• Cmax (Maximum Concentration) — the peak drug level achieved. Cmax reflects the rate of absorption — how quickly the drug reaches its highest concentration.
• Tmax (Time to Maximum Concentration) — when the peak occurs. Tmax is reported but not a formal bioequivalence criterion.

Acceptance criteria — the 90% confidence interval for the ratio of the generic's AUC and Cmax to the brand's AUC and Cmax must fall within 80% to 125%. In practice, most approved generics fall within a much narrower range — typically 95% to 105% of the brand product.

What Bioequivalence Means for Personal Injury Patients

For personal injury patients receiving medications through a pharmacy lien, bioequivalence has several practical implications:

Generic substitution is standard practice — when a prescriber writes a prescription for a brand-name drug and does not specify "Dispense as Written" (DAW), the pharmacist may — and in many states is required to — dispense an AB-rated bioequivalent generic. This is clinically appropriate and reduces costs without compromising treatment.

The medication record is accurate — even when the pharmacy record shows a generic product name instead of the brand name, the patient received a bioequivalent product that produces the same clinical effect. Attorneys reviewing pharmacy lien records should understand that generic dispensing does not represent a lesser treatment.

Narrow therapeutic index exceptions — for a small number of drugs with very narrow safety margins (warfarin, levothyroxine, phenytoin, certain immunosuppressants), even small differences in bioavailability can be clinically significant. Prescribers may specify DAW for these drugs to ensure consistent product dispensing.

Bioequivalence vs. Therapeutic Equivalence

These terms are related but distinct:

Bioequivalence is a pharmacokinetic measurement — it asks whether two products produce the same blood levels of the active drug.

Therapeutic equivalence is a broader FDA designation that includes bioequivalence plus pharmaceutical equivalence (same active ingredient, dosage form, strength, and route). An AB-rated product in the FDA Orange Book is both bioequivalent and therapeutically equivalent.

A product can be bioequivalent without being therapeutically equivalent if it differs in dosage form or strength. Conversely, pharmaceutical equivalents that have not undergone bioequivalence testing (B-rated products) are not considered therapeutically equivalent despite containing the same active ingredient.

Bioequivalence in the Legal Context

According to James Wong, PharmD, founder of LienScripts, bioequivalence is occasionally raised in personal injury litigation: "Defense counsel sometimes attempts to challenge medication records by noting that a generic — not the brand — was dispensed, implying inferior treatment. This argument has no pharmacological basis. An AB-rated generic is bioequivalent to the brand and produces the same clinical effect. The LienScripts pharmacy lien record includes the exact NDC number and manufacturer for every fill, providing complete transparency."

In rare cases where a patient has a documented adverse reaction to a specific generic manufacturer's product (which can occur due to inactive ingredient sensitivities, not active ingredient differences), this is documented in the medication record and the prescriber can specify a different manufacturer or the brand product.

Related Resources

• What Is a Therapeutic Equivalent?
• What Is a Compounded Medication?
• Generic vs. Brand Name Injury Medications
• What Is Step Therapy in Personal Injury?